What the business is, and whether it's a good one at a fair price.
Operates as a pharmaceutical company headquartered in Matunga, Mumbai, listed on the BSE SME Exchange. FY26 revenue was Rs 116.27 crore against total assets of Rs 94.21 crore. The cost structure shows zero materials cost, 2.6% employee costs and 13.6% other operating expenses, indicating the business is positioned around pharmaceutical trading, marketing or distribution rather than in-house drug manufacturing. The company is expanding overseas — it opened a representative branch office in Sharjah Media City Free Zone, UAE, commencing 31 March 2026, aimed at export opportunities and relationships with international clients. In FY26, short-term borrowings were reduced to Rs 1,393.92 lakhs and operating cash flow turned positive to Rs 923.57 lakhs from a negative figure the year before. Trade receivables at FY26 year-end stood at Rs 5,461.70 lakhs, indicating extended credit cycles to customers. The company is led by Managing Director Hemant C Bhagat and is exempt from detailed SEBI corporate governance norms under Regulation 15 because of its SME listing.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Not enough history to assess.How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from Chandra Bhagat Pharma Limited's filed financials and exchange disclosures
Chandra Bhagat Pharma Limited is a Pharmaceuticals & Biotechnology company listed on BSE.
No..
On trailing P/E, Chandra Bhagat Pharma Limited ranks 24 of 169 in Pharmaceuticals — cheaper than 86% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session Chandra Bhagat Pharma Limited moves 4.40% — that is the median absolute close-to-close move across its last 108 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by Chandra Bhagat Pharma Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
